Small companies often avoid the heart drug market, staying clear of the waters typically traversed by larger drugmakers who are more able to handle the risk associated with the larger and longer clinical trials required. Read More
Histone deacetylases (HDACs), the cellular enzymes whose functions include turning gene expression off and on, are promising targets in current drug development for cancer therapy. While treatment with HDAC inhibitors as monotherapies has demonstrated clinical benefit for patients with various hematological and solid tumor malignancies, there is excitement surrounding early results of their use together with other cancer therapeutics. That has spurred an increase in the research and development of treatment combinations with therapeutics such as checkpoint inhibitors. Read More
